3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Neuroblastoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Leukemia, Myelomonocytic, Chronic
2
Anemia, Refractory, with Excess of Blasts
2
Wilms Tumor
1
Uveal Melanoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Primary Malignant Peripheral Nerve Sheath Tumors
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Oligodendroglioma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Hepatoblastoma
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
GATA2 Deficiency
1
Breast Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Anemia, Refractory
1
Interventions
Cyclophosphamide
7
Biopsy
4
mogamulizumab
3
Specimen Handling
3
Peripheral Blood Stem Cell Transplantation
3
Etoposide
3
ruxolitinib
2
fludarabine phosphate
2
fludarabine
2
Whole-Body Irradiation
2
Vincristine
2
Tacrolimus
2
Prednisone
2
Nivolumab
2
Mycophenolic Acid
2
Magnetic Resonance Spectroscopy
2
Busulfan
2
tofacitinib
1
tazemetostat
1
talimogene laherparepvec
1
sodium-iodide symporter
1
pembrolizumab
1
hypericin
1
cemiplimab
1
belinostat
1
X-Rays
1
Vorinostat
1
Transplantation
1
Sirolimus
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell, Cutaneous
×
Vorinostat
×
90 days
×
Clear all
NCT02943642
2026-05-18
Resimmune®
Virogen Biotechnology Inc.
Phase 2
Withdrawn